Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923569 | 0.75 | ADORA3 (0.40) | ADORA3ADORA2AADORA1KDM4EALPL | |
| SCHEMBL14401184 | 0.70 | — | — | |
| SCHEMBL4784090 | 0.68 | HPGD (0.48) | KDM4ELMNAL3MBTL1HSD17B10 | |
| SCHEMBL10336585 | 0.68 | MAPT (0.49) | ADORA3ADORA2AADORA1KDM4EALPL | |
| SCHEMBL16922750 | 0.66 | GAA (0.38) | KDM4ELMNAALDH1A1 | |
| SCHEMBL9595465 | 0.65 | PTPN1 (0.33) | ADORA3ALDH1A1 | |
| SCHEMBL14513749 | 0.61 | MAPT (0.52) | LMNAL3MBTL1CYP2C19ALDH1A1HSD17B10 | |
| SCHEMBL17727039 | 0.61 | — | — | |
| SCHEMBL7923981 | 0.61 | CYP1A2 (0.64) | KDM4EALDH1A1 | |
| SCHEMBL7931736 | 0.61 | MAPT (0.38) | ADORA3ADORA1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | ADORA3 4034/4885ADORA2A 3899/4885ADORA1 4190/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | ADORA3 502/4885ADORA2A 841/4885ADORA1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.